


D/13  
1/17  
1800

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>Ashkenazi et al.</p> <p>Serial No.: 09/157,289</p> <p>Filed: September 18, 1998</p> <p>For: DcR3 Polypeptide, A TNFR Homolog</p> 	<p>Examiner: C. Kaufman</p> <p>Art Unit: 1646</p> <hr/> <p><b>CERTIFICATE OF MAILING</b></p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on</p> <p>December <u>14</u>, 1999</p> <p><i>Diane L. Marschang</i></p>
---	---

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATION CONTAINING SEQUENCE DISCLOSURES**

**Box Sequence**

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

This paper is being filed in response to the Office communication mailed August 30, 1999. Entry of the following amendment is requested.

IN THE SPECIFICATION:

Please enter into the specification the attached substitute paper copy of the Sequence Listing which includes 8 pages and provides sequences identified as SEQ ID NOS: 1-16.

**REMARKS**

On August 30, 1999, the Patent Office mailed an office action setting forth a Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures. In accordance with the requirements of 37 CFR Sections 1.821-1.825, Applicants are providing herewith a substitute paper copy of the Sequence Listing, along with a computer readable form of the Sequence Listing. The sequence disclosures in the Sequence Listing